ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TMDX TransMedics Group Inc

127.99
0.00 (0.00%)
Pre Market
Last Updated: 09:54:10
Delayed by 15 minutes
Share Name Share Symbol Market Type
TransMedics Group Inc NASDAQ:TMDX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 127.99 125.24 129.00 64 09:54:10

TransMedics to Report Second Quarter 2021 Financial Results on August 5, 2021

22/07/2021 9:05pm

PR Newswire (US)


TransMedics (NASDAQ:TMDX)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more TransMedics Charts.

ANDOVER, Mass., July 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter after market close on Thursday, August 5, 2021. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

(PRNewsfoto/TransMedics, Inc.)

Investors interested in listening to the conference call may do so by dialing (833) 378-1026 for domestic callers or (236) 712-2500 for international callers, followed by Conference ID: 9861546. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. 

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-second-quarter-2021-financial-results-on-august-5-2021-301339711.html

SOURCE TransMedics Group, Inc.

Copyright 2021 PR Newswire

1 Year TransMedics Chart

1 Year TransMedics Chart

1 Month TransMedics Chart

1 Month TransMedics Chart

Your Recent History

Delayed Upgrade Clock